RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
June 24, 2024 12:28 PM EDTMorgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $250.00 (from $164.00) while maintaining a Equalweight rating.
The analyst comments "Top-line HELIOS-B results better-than-expected, supporting sNDA filing in late 2024. We expect focus to now shift to presentation of... More
Alnylam Pharma (ALNY) out of the money July puts and January 260 calls active as share price up 38%
June 24, 2024 11:20 AM EDTAlnylam Pharma (NASDAQ: ALNY) 30-day option implied volatility is at 42; compared to its 52-week range of 33 to 408 as share price up 38% to $229.30 after reports results from its HELIOS-B Phase 3 study of vutrisiran. July 105 puts and 110 puts, September 85 puts and January 260 calls active at $13.20.
... MoreAlnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
June 24, 2024 7:58 AM EDTAlnylam Pharma (NASDAQ: ALNY) data is positive for Ionis Pharmaceuticals (NASDAQ: IONS) and Intellia Therapeutics (NASDAQ: NTLA) and negative for BridgeBio Pharma Inc. (NASDAQ: BBIO), according to analysts at BMO.... More
BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data
June 24, 2024 7:52 AM EDTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $234.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY). Earlier Alnylam reported positive topline results from HELIOS-B Phase 3 study of vutrisiran, achieving statistical significance on primary and all secondary endpoints in both overall and in the monotherapy... More
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
June 24, 2024 7:28 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "We believe topline HELIOS-B data are highly positive and support vutrisiran becoming a blockbuster in TTR-cardiomyopathy. Specifically the trial met all... More
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
June 24, 2024 7:11 AM EDTAlnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 a.m.
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
June 24, 2024 7:10 AM EDTBridgeBio Pharma (NASDAQ: BBIO) Trades Lower After Alnylam Pharma (NASDAQ: ALNY) Reports Positive Data
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy... MoreAlnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
June 24, 2024 7:00 AM EDT(Updated - June 24, 2024 7:27 AM EDT)
Alnylam Pharmaceuticals, Inc.... More
